Drug Trial Radar · NCT03277261
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
Last checked: Nov 20, 2026Latest source record: Dec 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
549
Actual
Start
Sep 19, 2017
Primary completion
Jul 23, 2020
Study completion Nov 6, 2020
Sponsor
- Lead sponsor
- TG Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 11, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study determines the Annualized Relapse Rate (ARR) in participants with RMS after 96 weeks (approximately 2 years) treatment with intravenous (IV) infusion of ublituximab/oral placebo compared to 14 mg oral teriflunomide/IV placebo.
Conditions
- Relapsing Multiple Sclerosis (RMS)
Interventions
UblituximabBiological
Administered as an IV infusion.
TeriflunomideDrug
Film-coated tablets administered orally.
Oral PlaceboDrug
Administered orally.
IV PlaceboDrug
Administered as an IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Relapse Rate (ARR)Time frame: Up to 96 weeks
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
TG Therapeutics RMS Investigational Trial Site
Carlsbad, California
TG Therapeutics RMS Investigational Trial Site
Long Beach, California
TG Therapeutics RMS Investigational Trial Site
Pasadena, California
TG Therapeutics RMS Investigational Trial Site
Stanford, California
TG Therapeutics RMS Investigational Trial Site
Miami, Florida
TG Therapeutics RMS Investigational Trial Site
Northbrook, Illinois
TG Therapeutics RMS Investigational Trial Site
Kansas City, Kansas
TG Therapeutics RMS Investigational Trial Site
Detroit, Michigan
TG Therapeutics RMS Investigational Trial Site
Amherst, New York
TG Therapeutics RMS Investigational Trial Site
Westerville, Ohio
TG Therapeutics RMS Investigational Trial Site
Franklin, Tennessee
TG Therapeutics RMS Investigational Trial Site
Knoxville, Tennessee
TG Therapeutics RMS Investigational Trial Site
Dallas, Texas
TG Therapeutics RMS Investigational Site
Round Rock, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.